Atlas Trials

A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation Model

Clinical trial NCT07239271 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07239271
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
NOT_YET_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Patients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy
Start date
2025-11-16
Primary completion
2027-12-01
Enrollment
2000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.